ALK inhibitors

Alectinib - Brigatinib - Ceritinib - Crizotinib      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultprogression or death (progression free survival PFS) death (overall survival)

lung cancer (metastatic)

alectinib
ALUR, 2018    NCTalectinibchemotherapy2L 2nd line crizotinib failure Exploratory suggesting-85%
ALEX, 2017      NCTalectinibcrizotinib1L 1st line Risk of bias conclusive-53%-24%
ceritinib
ASCEND-4, 2017      NCTceritinibchemotherapy1L 1st line nonsquamous NSCLC Risk of bias suggesting-45%-27%
ASCEND 5, 2017      NCTceritinibpemetrexed or docetaxel2L after crizotinib failure 2nd line crizotinib failure -
crizotinib
Shaw, 2013      NCTcrizotinibchemotherapy2L 2nd line Risk of bias suggesting-51%2%
PROFILE 1014, 2014        NCTcrizotinibchemotherapy1L 1st line nonsquamous NSCLC Risk of bias suggesting-55%-18%